Kong et al. developed a novel ADC drug, CLDN6-DM1 (DM1 being referred to as mertansine), and the preclinical data of CLDN6-DM1 showed robust antitumor effects against HCC cell lines and a xenograft mouse model, both as monotherapy and combined with sorafenib [144] (Table 4). This evidence concerns the gene CLDN6 and hepatocellular carcinoma.